On August 15, Tevogen Bio entered into a definitive agreement for a $6 million Series C Preferred Stock investment (“Series C”). The shares of the Series C have a 7.5% annual dividend and are ...
Tevogen Bio remains steadfast in its mission to pioneer accessible and affordable precision medicine while advocating for fair and transparent market participation.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback